组织工程与重建外科杂志

组织工程与重建外科杂志 >

2020 , Vol. 16 >Issue 3: 204 - 209

DOI: https://doi.org/10.3969/j.issn.1673-0364.2020.03.008

血管瘤和脉管畸形

静脉/淋巴管畸形靶向治疗的研究进展

展开
  • 1. 2000011　上海市　上海交通大学医学院附属第九人民医院整复外科(刘泓源,葛同鑫,林晓曦)
    2. 2000011　上海市　上海交通大学医学院附属第九人民医院激光美容科

收稿日期: 2020-04-08

  修回日期: 2020-04-24

  网络出版日期: 2020-06-26

基金资助

上海市申康临床技能与临床创新三年行动计划(16CR1007A);上海交通大学医学院附属第九人民医院临床研究助推计划“临+计划”(JYLJ001);上海交通大学医学院附属第九人民医院生物样本库专项基金(YBKA201902);上海交通大学医学院附属第九人民医院临床研究型MDT项目(201701001)

收起

Progress in Targeted Therapy of Low-Flow Vascular Malformation

Expand
  • 1. Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
    2. Department of Laser and Aesthetic Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

Received date: 2020-04-08

  Revised date: 2020-04-24

  Online published: 2020-06-26

Fold

摘要

随着精准医疗概念的提出及脉管畸形遗传学研究领域的突破,靶向药物治疗静脉/淋巴管畸形已成为目前的研究热点。静脉/淋巴管畸形被证实存在体细胞活化突变导致的PI3K/AKT/mTOR通路持续激活,是靶向治疗的基础。本文就靶向药物治疗静脉/淋巴管畸形方面的研究与应用进展进行综述。

关键词： 静脉畸形; 淋巴管畸形; 靶向治疗; 西罗莫司

本文引用格式

刘泓源, 葛同鑫, 林晓曦 . 静脉/淋巴管畸形靶向治疗的研究进展[J]. 组织工程与重建外科杂志, 2020 , 16(3) : 204 -209 . DOI: 10.3969/j.issn.1673-0364.2020.03.008

Abstract

With the introduction of the concept of precision medicine and the breakthrough in the genetics of vascular malformation, developing targeted therapies for low-flow vascular malformation has become a hot spot and urgent task of current research. Low-flow vascular malformation has been confirmed by the presence of somatic activation mutations leading to the continuous activation of the PI3K/AKT/ mTOR pathway, which indicates the possibility of targeted therapies. In this paper, the current researches and applications of targeted drugs in the treatment of low-flow vascular malformation were reviewed.

Key words： Venous malformation; Lymphatic malformation; Targeted therapy; Sirolimus

参考文献

[1] International Society for the Study of Vascular Anomalies. ISSVA classification for Vascular Anomalies [EB/OL]. ( 2018- 06- 30)[2020-04-22]. .
[2] 中华医学会整形外科分会血管瘤和脉管畸形学组. 血管瘤和脉管畸形的诊断及治疗指南(2019版)[J]. 组织工程与重建外科杂志, 2019,15(5):277-317.
[3] Dasgupta R, Patel M . Venous malformations[J]. Semin Pediatr Surg, 2014,23(4):198-202.
[4] Soblet J, Limaye N, Uebelhoer M , et al. Variable somatic TIE2 mutations in half of sporadic venous malformations[J]. Mol Syndromol, 2013,4(4):179-183.
[5] Limaye N, Wouters V, Uebelhoer M , et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations[J]. Nat Genet, 2009,41(1):118-124.
[6] Vikkula M, Boon LM , Carraway KL 3rd, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2[J]. Cell, 1996,87(7):1181-1190.
[7] Soblet J, Kangas J, N?tynki M , et al. Blue rubber bleb nevus (BRBN) syndrome is caused by somatic TEK (TIE2) mutations[J]. J Invest Dermatol, 2017,137(1):207-216.
[8] Limaye N, Kangas J, Mendola A , et al. Somatic activating PIK3CA mutations cause venous malformation[J]. Am J Hum Genet, 2015,97(6):914-921.
[9] Castel P, Carmona FJ, Grego-Bessa J , et al. Somatic PIK3CA mutations as a driver of sporadic venous malformations[J]. Sci Transl Med, 2016, 8(332):332ra42.
[10] Li X, Cai Y, Goines J , et al. Ponatinib combined with rapamycin causes regression of murine venous malformation[J]. Arterioscler Thromb Vasc Biol, 2019,39(3):496-512.
[11] Boscolo E, Limaye N, Huang L , et al. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects[J]. J Clin Invest, 2015,125(9):3491-3504.
[12] Castillo SD, Tzouanacou E, Zaw-Thin M , et al. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans[J]. Sci Transl Med, 2016, 8(332):332ra43.
[13] Tammela T, Alitalo K . Lymphangiogenesis: Molecular mechanisms and future promise[J]. Cell, 2010,140(4):460-476.
[14] Luks VL, Kamitaki N, Vivero MP , et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA[J]. J Pediatr, 2015,166(4):1048-1054.
[15] Osborn AJ, Dickie P, Neilson DE , et al. Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations[J]. Hum Mol Genet, 2015,24(4):926-938.
[16] Boscolo E, Coma S, Luks VL , et al. AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation[J]. Angiogenesis, 2015,18(2):151-162.
[17] Blesinger H, Kaulfu? S, Aung T , et al. PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations[J]. PLoS One, 2018,13(7):e0200343.
[18] Trenor CC 3rd, Chaudry G . Complex lymphatic anomalies[J]. Semin Pediatr Surg, 2014,23(4):186-190.
[19] Ozeki M, Fukao T . Generalized lymphatic anomaly and gorham-stout disease: overview and recent insights[J]. Adv Wound Care (New Rochelle), 2019,8(6):230-245.
[20] Hagendoorn J, Yock TI, Borel Rinkes IH , et al. Novel molecular pathways in Gorham disease: implications for treatment[J]. Pediatr Blood Cancer, 2014,61(3):401-406.
[21] Croteau SE, Kozakewich HP, Perez-Atayde AR , et al. Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly[J]. J Pediatr, 2014,164(2):383-388.
[22] Dellinger MT, Garg N, Olsen BR . Viewpoints on vessels and vanishing bones in Gorham-Stout disease[J]. Bone, 2014,63:47-52.
[23] Barclay SF, Inman KW, Luks VL , et al. A somatic activating NRAS variant associated with kaposiform lymphangiomatosis[J]. Genet Med, 2019,21(7):1517-1524.
[24] Boscolo E, Pastura P, Glaser K , et al. Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis[J]. Pediatr Blood Cancer, 2019,66(8):e27790.
[25] Rodriguez-Laguna L, Agra N, Iba?ez K , et al. Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly[J]. J Exp Med, 2019,216(2):407-418.
[26] Manevitz-Mendelson E, Leichner GS, Barel O , et al. Somatic NRAS mutation in patient with generalized lymphatic anomaly[J]. Angiogenesis, 2018,21(2):287-298.
[27] Li D, Wenger TL, Seiler C , et al. Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly[J]. Hum Mol Genet, 2018,27(18):3233-3245.
[28] Keppler-Noreuil KM, Rios JJ, Parker VE , et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation[J]. Am J Med Genet A, 2015,167A(2):287-295.
[29] Parker VER, Keppler-Noreuil KM, Faivre L , et al. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum[J]. Genet Med, 2019,21(5):1189-1198.
[30] Venot Q, Blanc T, Rabia SH , et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome[J]. Nature, 2018,558(7711):540-546.
[31] Gits CC, Nelson SC, Feltis BA , et al. Multimodal therapy in the treatment of a venolymphatic malformation of the axilla and chest wall in an infant[J]. J Vasc Surg Venous Lymphat Disord, 2014,2(4):451-454.
[32] Kim D, Benjamin L, Wysong A , et al. Treatment of complex periorbital venolymphatic malformation in a neonate with a combina-tion therapy of sirolimus and prednisolone[J]. Dermatol Ther, 2015,28(4):218-221.
[33] Goldenberg DC, Carvas M, Adams D , et al. Successful treatment of a complex vascular malformation with sirolimus and surgical resection[J]. J Pediatr Hematol Oncol, 2017,39(4):e191-e195.
[34] Hammer J, Seront E, Duez S , et al. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study[J]. Orphanet J Rare Dis, 2018,13(1):191.
[35] Mack JM, Verkamp B, Richter GT , et al. Effect of sirolimus on coagulopathy of slow-flow vascular malformations[J]. Pediatr Blood Cancer, 2019,66(10):e27896.
[36] Seront E, Van Damme A, Boon LM , et al. Rapamycin and treatment of venous malformations[J]. Curr Opin Hematol, 2019,26(3):185-192.
[37] Isoldi S, Belsha D, Yeop I , et al. Diagnosis and management of children with Blue Rubber Bleb Nevus Syndrome: A multi-center case series[J]. Dig Liver Dis, 2019,51(11):1537-1546.
[38] Yuksekkaya H, Ozbek O, Keser M , et al. Blue rubber bleb nevus syndrome: successful treatment with sirolimus[J]. Pediatrics, 2012,129(4):e1080-e1084.
[39] Salloum R, Fox CE, Alvarez-Allende CR , et al. Response of blue rubber bleb nevus syndrome to sirolimus treatment[J]. Pediatr Blood Cancer, 2016,63(11):1911-1914.
[40] Zhang B, Li L, Zhang N , et al. Efficacy and safety of sirolimus in the treatment of blue rubber bleb naevus syndrome in paediatric patients[J]. Clin Exp Dermatol, 2020,45(1):79-85.
[41] Wong XL, Phan K, Rodríguez Bandera AI , et al. Sirolimus in blue rubber bleb naevus syndrome: A systematic review[J]. J Paediatr Child Health, 2019,55(2):152-155.
[42] Couto JA, Vivero MP, Kozakewich HPW , et al. A somatic MAP3K3 mutation is associated with verrucous venous malformation[J]. Am J Hum Genet, 2015,96(3):480-486.
[43] Zhang G, Chen H, Zhen Z , et al. Sirolimus for treatment of verrucous venous malformation: A retrospective cohort study[J]. J Am Acad Dermatol, 2019,80(2):556-558.
[44] Cai R, Yang X, Gu H , et al. Sirolimus for the treatment of “verrucous” venous malformation: are we missing the lymphatic malformation component [J]? J Am Acad Dermatol, 2018: S0190- 9622(18) 32578-7.
[45] R?ssler J, Geiger J, F?ldi E , et al. Sirolimus is highly effective for lymph leakage in microcystic lymphatic malformations with skin involvement[J]. Int J Dermatol, 2017,56(4):e72-e75.
[46] Lagrèze WA, Joachimsen L, Gross N , et al. Sirolimus-induced regression of a large orbital lymphangioma[J]. Orbit, 2019,38(1):79-80.
[47] Ghariani Fetoui N, Boussofara L, Gammoudi R , et al. Efficacy of sirolimus in the treatment of microcystic lymphatic malformation of the tongue[J]. J Eur Acad Dermatol Venereol, 2019,33(9):e336-e337.
[48] Triana P, Miguel M, Díaz M , et al. Oral sirolimus: an option in the management of neonates with life-threatening upper airway lymphatic malformations[J]. Lymphat Res Biol, 2019,17(5):504-511.
[49] Alemi AS, Rosbe KW, Chan DK , et al. Airway response to sirolimus therapy for the treatment of complex pediatric lymphatic malformations[J]. Int J Pediatr Otorhinolaryngol, 2015,79(12):2466-2469.
[50] Strychowsky JE, Rahbar R , O'Hare MJ, et al. Sirolimus as treatment for 19 patients with refractory cervicofacial lymphatic malformation[J]. Laryngoscope, 2018,128(1):269-276.
[51] Tian R, Liang Y, Zhang W , et al. Effectiveness of sirolimus in the treatment of complex lymphatic malformations: Single center report of 56 cases[J]. J Pediatr Surg, 2020,[Epub ahead of print].
[52] Ozeki M, Nozawa A, Yasue S , et al. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies[J]. Orphanet J Rare Dis, 2019,14(1):141.
[53] Le Sage S, David M, Dubois J , et al. Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: A case series[J]. Pediatr Dermatol, 2018,35(4):472-477.
[54] García-Montero P, Del Boz J, Baselga-Torres E , et al. Use of topical rapamycin in the treatment of superficial lymphatic malformations[J]. J Am Acad Dermatol, 2019,80(2):508-515.
[55] Freixo C, Ferreira V, Martins J , et al. Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review[J]. J Vasc Surg, 2020,71(1):318-327.
[56] Ricci KW, Hammill AM, Mobberley-Schuman P , et al. Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease[J]. Pediatr Blood Cancer, 2019,66(5):e27614.
[57] Wang Z, Li K, Yao W , et al. Successful treatment of kaposiform lymphangiomatosis with sirolimus[J]. Pediatr Blood Cancer, 2015,62(7):1291-1293.
[58] Adams DM , Trenor CC 3rd, Hammill AM, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies[J]. Pediatrics, 2016,137(2):e20153257.
[59] Mori M, Dictor M, Brodszki N , et al. Pulmonary and pleural lymphatic endothelial cells from pediatric, but not adult, patients with Gorham-Stout disease and generalized lymphatic anomaly, show a high proliferation rate[J]. Orphanet J Rare Dis, 2016,11(1):67.
[60] Adams DM, Ricci KW . Vascular anomalies: diagnosis of complicated anomalies and new medical treatment options[J]. Hematol Oncol Clin North Am, 2019,33(3):455-470.
[61] Yesil S, Tanyildiz HG, Bozkurt C , et al. Single-center experience with sirolimus therapy for vascular malformations[J]. Pediatr Hematol Oncol, 2016,33(3):219-225.
[62] Dodds M, Tollefson M, Castelo-Soccio L , et al. Treatment of superficial vascular anomalies with topical sirolimus: A multicenter case series[J]. Pediatr Dermatol, 2020,37(2):272-277.
[63] Badia P, Ricci K, Gurria JP , et al. Topical sirolimus for the treatment of cutaneous manifestations of vascular anomalies: A case series[J]. Pediatr Blood Cancer, 2020,67(4):e28088.
[64] Vlahovic AM, Vlahovic NS, Haxhija EQ . Sirolimus for the treatment of a massive capillary-lymphatico-venous malformation: a case report[J]. Pediatrics, 2015,136(2):e513-e516.
[65] Bessis D, Vernhet H, Bigorre M , et al. Life-threatening cutaneous bleeding in childhood klippel-trenaunay syndrome treated with oral sirolimus[J]. JAMA Dermatol, 2016,152(9):1058-1059.
[66] González-Hermosa MR, Guerra E, Tuduri I , et al. CLAPO syndrome: Effective response to treatment with oral rapamycin[J]. Dermatol Ther, 2019,32(4):e12991.
[67] Lee RA, Gabardi S . Current trends in immunosuppressive therapies for renal transplant recipients[J]. Am J Health Syst Pharm, 2012,69(22):1961-1975.
[68] Nadal M, Giraudeau B, Tavernier E , et al. Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: a systematic review[J]. Acta Derm Venereol, 2016,96(4):448-452.
[69] Wiegand S, Wichmann G, Dietz A . Treatment of lymphatic malformations with the mTOR inhibitor sirolimus: a systematic review[J]. Lymphat Res Biol, 2018,16(4):330-339.
[70] Ying H, Qiao C, Yang X , et al. A case report of 2 sirolimus-related deaths among infants with kaposiform hemangioendo the liomas[J]. Pediatrics, 2018,141(Suppl 5):S425-S429.
[71] Morath C, Arns W, Schwenger V , et al. Sirolimus in renal transplantation[J]. Nephrol Dial Transplant, , 2007,22(Suppl 8):viii61-viii65.
[72] EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients[J]. Nephrol Dial Transplant, 2002,17 Suppl 4: 50-55.
[73] Zuber J, Anglicheau D, Elie C , et al. Sirolimus may reduce fertility in male renal transplant recipients[J]. Am J Transplant, 2008,8(7):1471-1479.
[74] González D, García CD, Azócar M , et al. Growth of kidney-transplanted pediatric patients treated with sirolimus[J]. Pediatr Nephrol, 2011,26(6):961-966.
[75] López Gutiérrez JC, Lizarraga R, Delgado C , et al. Alpelisib treatment for genital vascular malformation in a patient with congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and spinal/skeletal anomalies and/or scoliosis (CLOVES) syndrome[J]. J Pediatr Adolesc Gynecol, 2019,32(6):648-650.
Options
文章导航

/

〈 〉